Trial Profile
A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) With Paclitaxel in Patients With Triple Negative Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer
- Focus Adverse reactions
- 20 Nov 2023 Status changed from active, no longer recruiting to completed.
- 15 May 2023 Planned End Date changed from 1 Aug 2023 to 1 Jan 2024.
- 04 May 2021 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.